Cost effectiveness of fibrosis assessment prior to treatment for chronic hepatitis C patients.
<h4>Background and aims</h4>Chronic hepatitis C (HCV) is a liver disease affecting over 3 million Americans. Liver biopsy is the gold standard for assessing liver fibrosis and is used as a benchmark for initiating treatment, though it is expensive and carries risks of complications. Fibr...
Saved in:
Main Authors: | Shan Liu, Michaël Schwarzinger, Fabrice Carrat, Jeremy D Goldhaber-Fiebert |
---|---|
Format: | article |
Language: | EN |
Published: |
Public Library of Science (PLoS)
2011
|
Subjects: | |
Online Access: | https://doaj.org/article/cee6a3f304084a5b9154e1af5ab1e793 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Chronic hepatitis C: future treatment
by: Wendt A, et al.
Published: (2014) -
Role of PNPLA3 in the Assessment and Monitoring of Hepatic Steatosis and Fibrosis in Patients with Chronic Hepatitis C Infection Who Achieved a Sustained Virologic Response
by: Oana Irina Gavril, et al.
Published: (2021) -
Diagnosis and staging of fibrosis in patients with chronic hepatitis C: comparison and critical overview of current strategies
by: Mendes LC, et al.
Published: (2018) -
Review of consensus interferon in the treatment of chronic hepatitis C
by: Th Witth&ouml;ft
Published: (2008) -
Quality of life and adherence to treatment of patients with chronic viral hepatitis C
by: R. S. Mirkhaydarov, et al.
Published: (2018)